在一家碳青霉烯类肺炎克雷伯菌介导的碳青霉烯类耐药率较低的三级医疗中心，对美罗培南-巴坦姆对临床耐碳青霉烯类肠杆菌科细菌（CRE）分离株进行体外评估。
In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
作者信息
Kinn Patrick M, Chen Derrick J, Gihring Thomas M, Schulz Lucas T, Fox Barry C, McCreary Erin K, Lepak Alexander J
机构信息
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Clinical Labs - Microbiology, UW Health, Madison, WI, USA; Department of Pharmacy, UW Health, Madison, WI, USA.
出版信息
Diagn Microbiol Infect Dis. 2019 Mar;93(3):258-260. doi: 10.1016/j.diagmicrobio.2018.09.017. Epub 2018 Oct 4.
The in vitro activity of meropenem-vaborbactam was examined against clinical carbapenem-resistant Enterobacteriaceae isolates collected over 3 years at our medical center. Only 3 KPC-producers were identified. Susceptibility to meropenem-vaborbactam was noted in 15/16 (94%) isolates (MIC 2 mg/L) that were nonsusceptible to meropenem. Meropenem-vaborbactam may have utility at centers where non-KPC-producers are more frequent.
对美罗培南-巴坦制剂的体外活性进行了检测，检测对象为我们医疗中心在3年多时间里收集的临床耐碳青霉烯类肠杆菌科分离株。仅鉴定出3株产KPC酶的菌株。在对美罗培南不敏感的16株分离株中有15株（94%）（MIC为2mg/L）对美罗培南-巴坦制剂敏感。在非产KPC酶菌株更常见的医疗中心，美罗培南-巴坦制剂可能有用。
Zotero 插件